Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial findsBMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2650 (Published 01 July 2020) Cite this as: BMJ 2020;370:m2650
- Shaun Griffin
The anti-HIV drug lopinavir-ritonavir does not improve survival of patients with covid-19 in hospital, according to new findings from the UK RECOVERY trial.
Announcing the results, which are yet to be formally peer reviewed, Martin Landray, deputy chief investigator, said that current guidelines in many countries recommend lopinavir-ritonavir as a treatment for covid-19. “The results from this trial [and] other large randomised trials should inform revisions to those guidelines and changes to the way individual patients are treated,” he said.
The data showed that, at 28 days, the death rate was not significantly different in patients …